Publications

BibTex format

@article{Anderson:2019:10.1038/s41571-018-0134-8,
author = {Anderson, RL and Balasas, T and Callaghan, J and Coombes, RC and Evans, J and Hall, JA and Kinrade, S and Jones, D and Jones, PS and Jones, R and Marshall, JF and Panico, MB and Shaw, JA and Steeg, PS and Sullivan, M and Tong, W and Westwell, AD and Ritchie, JWA and Berg, R and Drysdale, M and Eccles, S and Elvin, P and Harris, A and Ireson, C and Machesky, L and McLeod, R and Muschel, R and Newell, H and Pittman, M and Roman, B and Santos, C and Sibson, N and Smith, A and Waddell, I},
doi = {10.1038/s41571-018-0134-8},
journal = {Nature Reviews Clinical Oncology},
pages = {185--204},
title = {A framework for the development of effective anti-metastatic agents},
url = {http://dx.doi.org/10.1038/s41571-018-0134-8},
volume = {16},
year = {2019}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Most cancer-related deaths are a result of metastasis, and thus the importance of this process as a target of therapy cannot be understated. By asking ‘how can we effectively treat cancer?’, we do not capture the complexity of a disease encompassing >200 different cancer types — many consisting of multiple subtypes — with considerable intratumoural heterogeneity, which can result in variable responses to a specific therapy. Moreover, we have much less information on the pathophysiological characteristics of metastases than is available for the primary tumour. Most disseminated tumour cells that arrive in distant tissues, surrounded by unfamiliar cells and a foreign microenvironment, are likely to die; however, those that survive can generate metastatic tumours with a markedly different biology from that of the primary tumour. To treat metastasis effectively, we must inhibit fundamental metastatic processes and develop specific preclinical and clinical strategies that do not rely on primary tumour responses. To address this crucial issue, Cancer Research UK and Cancer Therapeutics CRC Australia formed a Metastasis Working Group with representatives from not-for-profit, academic, government, industry and regulatory bodies in order to develop recommendations on how to tackle the challenges associated with treating (micro)metastatic disease. Herein, we describe the challenges identified as well as the proposed approaches for discovering and developing anticancer agents designed specifically to prevent or delay the metastatic outgrowth of cancer.
AU  - Anderson,RL
AU  - Balasas,T
AU  - Callaghan,J
AU  - Coombes,RC
AU  - Evans,J
AU  - Hall,JA
AU  - Kinrade,S
AU  - Jones,D
AU  - Jones,PS
AU  - Jones,R
AU  - Marshall,JF
AU  - Panico,MB
AU  - Shaw,JA
AU  - Steeg,PS
AU  - Sullivan,M
AU  - Tong,W
AU  - Westwell,AD
AU  - Ritchie,JWA
AU  - Berg,R
AU  - Drysdale,M
AU  - Eccles,S
AU  - Elvin,P
AU  - Harris,A
AU  - Ireson,C
AU  - Machesky,L
AU  - McLeod,R
AU  - Muschel,R
AU  - Newell,H
AU  - Pittman,M
AU  - Roman,B
AU  - Santos,C
AU  - Sibson,N
AU  - Smith,A
AU  - Waddell,I
DO  - 10.1038/s41571-018-0134-8
EP  - 204
PY  - 2019///
SN  - 1759-4774
SP  - 185
TI  - A framework for the development of effective anti-metastatic agents
T2  - Nature Reviews Clinical Oncology
UR  - http://dx.doi.org/10.1038/s41571-018-0134-8
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459172400011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/101473
VL  - 16
ER  -

Download

ProfessorCharlesCoombes

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)